Development and characterization of pediatric osteosarcoma xenografts

scientific article published on 01 May 1990

Development and characterization of pediatric osteosarcoma xenografts is …
instance of (P31):
scholarly articleQ13442814

External links are
P698PubMed publication ID2328504

P2093author name stringLook AT
Houghton PJ
Douglass EC
Houghton JA
Meyer WH
Webber BL
P433issue9
P407language of work or nameEnglishQ1860
P921main subjectpediatric osteosarcomaQ18555393
P304page(s)2781-2785
P577publication date1990-05-01
P1433published inCancer ResearchQ326097
P1476titleDevelopment and characterization of pediatric osteosarcoma xenografts
P478volume50

Reverse relations

cites work (P2860)
Q40887213A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies
Q44142983Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts
Q34243816Anti-angiogenic activity of a small molecule STAT3 inhibitor LLL12.
Q40608512Biological properties and gene expression associated with metastatic potential of human osteosarcoma
Q90316280Challenges and Opportunities for Childhood Cancer Drug Development
Q40693752Establishment of human osteosarcoma cell lines with high metastatic potential to lungs and their utilities for therapeutic studies on metastatic osteosarcoma
Q45168481Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors
Q39329335Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue
Q45078434Human osteosarcoma xenografts and their sensitivity to chemotherapy
Q73193294Human pancreatic leiomyosarcoma (PZX-7) growing as a serially transplantable xenograft in immunosuppressed mice
Q52311090Patient-derived xenograft models in musculoskeletal malignancies.
Q41175743Pediatric drug development: a perspective from the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI).
Q34414730The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma

Search more.